Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Torres Iglesias

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
European Journal of Case Reports in Internal Medicine|November 13, 2025
Tofacitinib Improves Motor Symptoms in Parkinsonism Associated with a Heterozygous NGLY1 Variant and Autoimmune DiseaseNuria Reina-Llompart, Soledad Serrano-López, Gabriel Torres-Iglesias, et al.
European Journal of Case Reports in Internal Medicine|November 13, 2025
Erratum: [Erratum] Tofacitinib Improves Motor Symptoms in Parkinsonism Associated with a Heterozygous NGLY1 Variant and Autoimmune DiseaseNuria Reina-Llompart, Soledad Serrano-López, Gabriel Torres-Iglesias, et al.
Frontiers in Neurology|March 8, 2021
A New Software for Quantifying Motor Deficit After Stroke: A Case-Control Feasibility Pilot StudyRaquel Gutiérrez Zúñiga, María Alonso de Leciñana, Alejandro Díez, et al.
International Journal of Molecular Sciences|September 28, 2023
Antibody Content against Epstein-Barr Virus in Blood Extracellular Vesicles Correlates with Disease Activity and Brain Volume in Patients with Relapsing-Remitting Multiple SclerosisMireya Fernández-Fournier, MariPaz López-Molina, Gabriel Torres Iglesias, et al.
International Journal of Molecular Sciences|October 16, 2024
Differential Protein Expression in Extracellular Vesicles Defines Treatment Responders and Non-Responders in Multiple SclerosisGabriel Torres Iglesias, MariPaz López-Molina, Lucía Botella, et al.
Diseases (Basel, Switzerland)|December 24, 2025
Immunological Monitoring During Anti-CD20 Therapies to Predict Infection Risk and Treatment Response in Multiple Sclerosis PatientsGabriel Torres Iglesias, Ana Martínez-Feito, Laura Otero-Ortega, et al.
Digital Health|January 30, 2025
Digital tool as speech and language therapy for patients with post-stroke aphasiaGerardo Ruiz Ares, Marta Martin Alonso, Ricardo Rigual, et al.
Journal of Neurology|April 5, 2024
Keeping prior anticoagulation treatment in the acute phase of ischaemic stroke: the REKOALA studyRicardo Rigual, Jorge Rodríguez-Pardo, Manuel Lorenzo-Diéguez, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 19, 2025
Extracellular Vesicle-Derived MicroRNAs as a Biomarker for Therapeutic Response in Multiple SclerosisGabriel Torres-Iglesias, MariPaz López-Molina, Rubén Ayala-Suárez, et al.
Frontiers in Immunology|November 5, 2025
Immune checkpoint-based biomarkers for therapeutic response in patients with multiple sclerosisMariPaz López-Molina, Gabriel Torres Iglesias, Gonzalo Sáenz de Santa María-Diez, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
European Journal of Case Reports in Internal Medicine|November 13, 2025
Tofacitinib Improves Motor Symptoms in Parkinsonism Associated with a Heterozygous NGLY1 Variant and Autoimmune DiseaseNuria Reina-Llompart, Soledad Serrano-López, Gabriel Torres-Iglesias, et al.
European Journal of Case Reports in Internal Medicine|November 13, 2025
Erratum: [Erratum] Tofacitinib Improves Motor Symptoms in Parkinsonism Associated with a Heterozygous NGLY1 Variant and Autoimmune DiseaseNuria Reina-Llompart, Soledad Serrano-López, Gabriel Torres-Iglesias, et al.
Frontiers in Neurology|March 8, 2021
A New Software for Quantifying Motor Deficit After Stroke: A Case-Control Feasibility Pilot StudyRaquel Gutiérrez Zúñiga, María Alonso de Leciñana, Alejandro Díez, et al.
International Journal of Molecular Sciences|September 28, 2023
Antibody Content against Epstein-Barr Virus in Blood Extracellular Vesicles Correlates with Disease Activity and Brain Volume in Patients with Relapsing-Remitting Multiple SclerosisMireya Fernández-Fournier, MariPaz López-Molina, Gabriel Torres Iglesias, et al.
International Journal of Molecular Sciences|October 16, 2024
Differential Protein Expression in Extracellular Vesicles Defines Treatment Responders and Non-Responders in Multiple SclerosisGabriel Torres Iglesias, MariPaz López-Molina, Lucía Botella, et al.
Diseases (Basel, Switzerland)|December 24, 2025
Immunological Monitoring During Anti-CD20 Therapies to Predict Infection Risk and Treatment Response in Multiple Sclerosis PatientsGabriel Torres Iglesias, Ana Martínez-Feito, Laura Otero-Ortega, et al.
Digital Health|January 30, 2025
Digital tool as speech and language therapy for patients with post-stroke aphasiaGerardo Ruiz Ares, Marta Martin Alonso, Ricardo Rigual, et al.
Journal of Neurology|April 5, 2024
Keeping prior anticoagulation treatment in the acute phase of ischaemic stroke: the REKOALA studyRicardo Rigual, Jorge Rodríguez-Pardo, Manuel Lorenzo-Diéguez, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 19, 2025
Extracellular Vesicle-Derived MicroRNAs as a Biomarker for Therapeutic Response in Multiple SclerosisGabriel Torres-Iglesias, MariPaz López-Molina, Rubén Ayala-Suárez, et al.
Frontiers in Immunology|November 5, 2025
Immune checkpoint-based biomarkers for therapeutic response in patients with multiple sclerosisMariPaz López-Molina, Gabriel Torres Iglesias, Gonzalo Sáenz de Santa María-Diez, et al.
Pageof 2